Short answer
Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Aardvark Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Business updates included in November 13, 2026 press release
- Exhibit 99.1 contains the detailed results and operational disclosures
Item EX-99.1 · Exhibit EX-99.1
- FDA lifted ARD-101’s PWS clinical hold, enabling an open-label trial at 200 mg twice daily
- FDA meeting scheduled for Q1 2027, with PWS clinical activities expected to resume in 2027 subject to alignment
- Terminated HERO trial showed numerically greater HQ-CT reductions versus placebo, but 67 participants and declining evaluable counts make efficacy inconclusive
- Cardiac safety studies found no QRS or QT prolongation at 200 mg or 400 mg twice daily
- Cash $60.3M at September 30, 2026 supports projected operations through 2027, while quarterly net loss rose to $19.2M from $16.3M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aardvark Therapeutics, Inc. 8-K filings
Get the next AARD 8-K as it lands
Follow AARD for push alerts, or ask the research agent what this filing means.